SecurityBIIB / Biogen Inc.
InstitutionBridgewater Associates, LP
ManagerRay Dalio, Bob Prince
Shares22,819
Value $ 6,623,000
Related 09062XAE3 / Biogen Inc. Bond

Bridgewater Associates, LP reports 70.44% decrease in ownership of BIIB / Biogen Inc.

August 13, 2018 - Bridgewater Associates, LP has filed a 13F-HR form disclosing ownership of 22,819 shares of Biogen Inc. (NASDAQ:BIIB) with total holdings valued at $6,623,000 USD as of June 30, 2018. Bridgewater Associates, LP had filed a previous 13F-HR on May 15, 2018 disclosing 77,197 shares of Biogen Inc. at a value of $21,138,000 USD. This represents a change in shares of -70.44 percent and a change in value of -68.67 percent during the quarter.

Other investors with positions similar to Bridgewater Associates, LP include Bridges Investment Management Inc, BlueMountain Capital Management, LLC, Citizens Financial Group Inc/RI, Livforsakringsbolaget Skandia, Omsesidigt, Delta Lloyd Asset Management N.v., and Sivik Global Healthcare LLC.

Biogen Inc. has declared a standard industrial code (sic) of 2836 which is the "Biological Products, Except Diagnostic Substances (Biotech)" industry. Bridgewater Associates, LP's top industries are "Printing, Publishing, And Allied Industries" (sic 27), "Rubber And Miscellaneous Plastics Products" (sic 30), and "Stone, Clay, Glass, And Concrete Products" (sic 32).

Bridgewater Associates, LP reports 70.44% decrease in  ownership of BIIB / Biogen Inc.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR BIOGEN COM 09062X103 282.03 22,819 -70.44 6,623 -68.67 -15,336 821 3.89
2018-03-31 13F-HR BIOGEN COM 09062X103 77,197 21,138 21,138 0
2017-12-31 13F-HR BIOGEN COM 09062X103 0 -100.00 0 -100.00 -13,839 0
2017-09-30 13F-HR BIOGEN COM 09062X103 292.24 44,198 -1.74 13,839 13.38 -229 1,862 15.25
2017-06-30 13F-HR BIOGEN COM 09062X103 272.39 44,981 -1.03 12,206 -1.77 -127 -93 -0.75
2017-03-31 13F-HR BIOGEN COM 09062X103 45,447 12,426 12,426 0
2016-12-31 13F-HR BIOGEN COM 09062X103 0 -100.00 0 -100.00 -282 0
2016-09-30 13F-HR BIOGEN COM 09062X103 277.57 900 -98.25 282 -97.73 -14,034 1,872 15.05
2016-06-30 13F-HR BIOGEN COM 09062X103 251.07 51,461 122.72 12,444 106.88 7,119 -690 -11.47
2016-03-31 13F-HR BIOGEN COM 09062X103 283.33 23,106 -7.97 6,015 -21.79 -567 -1,109 -14.42
2015-12-31 13F-HR BIOGEN COM 09062X103 299.08 25,106 70.03 7,691 78.49 3,092 290 6.72
2015-09-30 13F-HR BIOGEN COM 09062X103 14,766 0.00 4,309 4,309 0
2015-06-30 13F-HR BIOGEN COM 09062X103 0 -100.00 0 -100.00 -8,633 0
2015-03-31 13F-HR BIOGEN COM 09062X103 380.83 20,446 34.99 8,633 67.92 2,018 1,474 28.66
2014-12-31 13F-HR BIOGEN IDEC COM 09062X103 335.27 15,146 820.17 5,141 843.30 4,526 70 12.82
2014-09-30 13F-HR BIOGEN IDEC COM 09062X103 305.34 1,646 -91.36 545 -89.77 -5,316 533 10.01
2013-12-31 13F-HR BIOGEN IDEC COM 09062X103 260.13 19,057 208.67 5,328 258.55 3,351 491 33.02
2013-09-30 13F-HR BIOGEN IDEC COM 09062X103 227.93 6,174 -41.27 1,486 -34.31 -989 213 9.41
2013-06-30 13F-HR BIOGEN IDEC COM 09062X103 10,512 2,262

Related SEC Filings

BIIB / Biogen Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
biogeninc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Biogen Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  09062X103     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)   ( 

BIIB / Biogen Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
biogeninc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Biogen Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  09062X103     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-1(b)   ( 

BIIB / Biogen Inc. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-29 sec.gov
us09062x1037_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) BIOGEN INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 09062X103 -------------------------------------------------------- (CUSIP Number) December 31, 2017 -------------------------------------------------------- (D

Related News Stories

Corium's (CORI) Shares Surge on Merger Agreement With Gurnet

2018-10-15 zacks
Corium International, Inc. (CORI - Free Report) announced that it has entered a definitive merger agreement with a private investment firm, Gurnet Point Capital. Per this agreement, Gurnet will acquire Corium and will also take the company private. (2-0)

The October Pause That Refreshes

2018-10-11 seekingalpha
The much-awaited correction is finally here; the question is who will step up to the plate and will actually use it as a long-term buying opportunity. (36-0)

Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing

2018-10-11 zacks
Teva Pharmaceutical Industries Limited (TEVA - Free Report) along with South Korean partner Celltrion Inc. announced that the FDA’s Oncologic Drugs Advisory Committee has voted unanimously (16-0) recommending approval of CT-P10, their proposed monoclonal antibody (mAb) biosimilar to Roche’s (RHHBY - Free Report) Rituxan. (19-0)

Novartis Presents Data on Multiple Sclerosis Drug Gilenya

2018-10-11 zacks
Novartis AG (NVS - Free Report) announced encouraging top-line results from the phase IIIb ASSESS study on multiple sclerosis drug, Gilenya. (12-0)

The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC

2018-10-11 zacks
Chicago, IL –October 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Altria (MO - Free Report) , U.S. Bancorp (USB - Free Report) ,Biogen (BIIB - Free Report) , Ecolab (ECL - Free Report) and HSBC Holdings (HSBC - Free Report) . (20-0)



CUSIP: 09062X103